Chinese Medicine Amygdalin and β-Glucosidase Combined with Antibody Enzymatic Prodrug System As A Feasible Antitumor Therapy / 中国结合医学杂志
Chinese journal of integrative medicine
; (12): 237-240, 2018.
Article
en En
| WPRIM
| ID: wpr-691402
Biblioteca responsable:
WPRO
ABSTRACT
Amarogentin is an efficacious Chinese herbal medicine and a component of the bitter apricot kernel. It is commonly used as an expectorant and supplementary anti-cancer drug. β-Glucosidase is an enzyme that hydrolyzes the glycosidic bond between aryl and saccharide groups to release glucose. Upon their interaction, β-glucosidase catalyzes amarogentin to produce considerable amounts of hydrocyanic acid, which inhibits cytochrome C oxidase, the terminal enzyme in the mitochondrial respiration chain, and suspends adenosine triphosphate synthesis, resulting in cell death. Hydrocyanic acid is a cell-cycle-stage-nonspecific agent that kills cancer cells. Thus, β-glucosidase can be coupled with a tumor-specific monoclonal antibody. β-Glucosidase can combine with cancer-cell-surface antigens and specifically convert amarogentin to an active drug that acts on cancer cells and the surrounding antibodies to achieve a killing effect. β-Glucosidase is injected intravenously and recognizes cancer-cell-surface antigens with the help of an antibody. The prodrug amarogentin is infused after β-glucosidase has reached the target position. Coupling of cell membrane peptides with β-glucosidase allows the enzyme to penetrate capillary endothelial cells and clear extracellular deep solid tumors to kill the cells therein. The Chinese medicine amarogentin and β-glucosidase will become an important treatment for various tumors when an appropriate monoclonal antibody is developed.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Profármacos
/
Beta-Glucosidasa
/
Iridoides
/
Usos Terapéuticos
/
Péptidos de Penetración Celular
/
Amigdalina
/
Anticuerpos Monoclonales
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Chinese journal of integrative medicine
Año:
2018
Tipo del documento:
Article